Aptar Pharma India Profile
Key Indicators
- Authorised Capital ₹ 7.80 Cr
as on 21-12-2024
- Paid Up Capital ₹ 7.44 M
as on 21-12-2024
- Company Age 25 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 23.32%
(FY 2022)
- Profit 39.22%
(FY 2022)
- Ebitda 29.91%
(FY 2022)
- Net Worth 69.37%
(FY 2022)
- Total Assets 20.54%
(FY 2022)
About Aptar Pharma India
The Corporate was formerly known as Valois India Private Limited. The Company is engaged in the Packaging Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.80 Cr and a paid-up capital of Rs 7.44 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Kapote, Gael Touya, and Anand Hiremath serve as directors at the Company.
- CIN/LLPIN
U29195MH1999PTC207807
- Company No.
207807
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 1999
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Aptar Pharma India Private Limited offer?
Aptar Pharma India Private Limited offers a wide range of products and services, including Plastic Containers & Bottles, Cosmetic Bottle, Packaging Caps & Seals, Cap Closures.
Who are the key members and board of directors at Aptar Pharma India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Kapote  | Director | 13-Mar-2023 | Current |
Gael Touya  | Director | 11-Feb-2019 | Current |
| Anand Hiremath | Director | 28-Jun-2022 | Current |
Financial Performance of Aptar Pharma India.
Aptar Pharma India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.32% increase. The company also saw a substantial improvement in profitability, with a 39.22% increase in profit. The company's net worth Soared by an impressive increase of 69.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aptar Pharma India?
In 2022, Aptar Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aptar Pharma India?
Aptar Pharma India has a workforce of 320 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aptar Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aptar Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
